Takeda Pharmaceutical Company Limited Share Price Fukuoka Stock Exchange
Equities
4502
JP3463000004
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,080 JPY | -1.21% | -.--% | +2.13% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.15B 2,137B | Sales 2025 * | 4,097B 26.08B 2,053B | Capitalization | 6,486B 41.3B 3,250B |
---|---|---|---|---|---|
Net income 2024 | 144B 917M 72.19B | Net income 2025 * | 136B 864M 68.01B | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.01B 1,890B | Net Debt 2025 * | 4,204B 26.77B 2,107B | EV / Sales 2025 * | 2.61 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | - |
Yield 2024 * |
4.55% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 month | -5.01% | ||
Current year | +2.13% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 31/03/14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/01/22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 31/05/16 | |
Ian Clark
BRD | Director/Board Member | 62 | 31/12/18 |
Steven Gillis
BRD | Director/Board Member | 71 | 31/12/18 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.59% | 723B | |
+34.28% | 595B | |
-4.04% | 369B | |
+20.29% | 332B | |
+2.85% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock